Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Supernus: Q4 Earnings Snapshot

Supernus: Q4 Earnings Snapshot

SUPN : 26.80 (+0.53%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 26.80 (+0.53%)
Supernus: Q2 Earnings Snapshot

Supernus: Q2 Earnings Snapshot

SUPN : 26.80 (+0.53%)
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy

Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way.

SUPN : 26.80 (+0.53%)
Supernus: Q1 Earnings Snapshot

Supernus: Q1 Earnings Snapshot

SUPN : 26.80 (+0.53%)
Supernus: Q4 Earnings Snapshot

Supernus: Q4 Earnings Snapshot

SUPN : 26.80 (+0.53%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 26.80 (+0.53%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 26.80 (+0.53%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 26.80 (+0.53%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 26.80 (+0.53%)

Barchart Exclusives

Forget GameStop, Here's the Old-School Retail Stock Analysts Are Betting On
After its well-received earnings report, analysts at UBS upgraded Best Buy, predicting more upside ahead for the big-box retailer. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar